Can a new daily lens match the comfort of a proven one?

NCT ID NCT06995781

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial is testing whether a new daily disposable contact lens, PEGAVISION G3, is as safe and effective as an existing lens (Clariti 1 day) for correcting nearsightedness. Adults with mild to moderate myopia will wear the lenses for three months, and researchers will measure vision sharpness and check for any eye problems. The goal is to see if the new lens provides clear, comfortable vision without causing harm.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PEGAVISION G3 silicone hydrogel daily disposable soft contact lenses
What this could lead to
If successful, this could provide a new daily disposable contact lens option that offers comparable vision correction and comfort for people with myopia.
What could go wrong
This is a relatively small, early-stage trial, and results may not reflect real-world use. As with any contact lens, there is a risk of eye irritation or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

69 people

The number who actually took part.

Started

Jan 2025

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects must be at least 18 years of age on the date the ICF is signed and have the capacity to provide voluntary informed consent. 2. Subjects must be myopic and require lens correction from -1.00 to -8.00 Diopter (D) with ≤ 1.00 D astigmatism in each eye. 3. Subjects must be correctable through spherocylindrical refraction to Log Mar 0.1 or better in each eye. 4. Subjects must be adapted to soft contact lens wearers. 5. Subjects agree to follow the protocol and are willing to wear their study lenses for at least 8 hours per day at least 5 days per week on a daily disposable wear basis during the study. Exclusion Criteria: 1. Subjects who exhibit allergies to contact lens materials, contact lens packaging solutions, or possess a history of allergies that contraindicate conventional contact lens wear. 2. Subjects live in environments unsuitable for soft lens wear (like areas with dust, chemicals, aerosols). 3. Subjects presenting with active ocular conditions. These conditions include, but are not limited to, uveitis, corneal hypoesthesia, corneal epithelial defect, severe dry eye, lacrimal duct defect, glaucoma, cornea \[infiltrates\], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology. 4. Use of systemic medications that are known to interfere with contact lenses wear at the investigator's discretion. 5. Currently pregnant (to the best of the Subject's knowledge), lactating or planning a pregnancy within the next 3 months 6. Any active participation in any contact lens or lens care product clinical trial within fourteen days prior to this study. 7. The presence of clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures. 8. Subject has a known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates or fungal infections. 9. Subject has a history of papillary conjunctivitis that has interfered with contact lens wear. 10. Subject has a history of herpetic keratitis retinal detachment or irregular cornea. 11. Subject has a history of recurrent eye or eyelid infections, adverse effects associated with your contact lens wear, intolerance or an unusual response to your contact lens wear. 12. The Subject currently has pathological dry eye (tear break-up time ≤ 5 seconds). 13. Subjects who have undergone or plan to undergo corneal or intraocular surgery during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Refractive error - myopia simple are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.